Recent research have centered on the intersection of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|glucagon receptor activator therapies and dopaminergic communication. While GCGR agonists are increasingly employed for addressing type 2 diabetes, their unexpected impacts on